1
|
Zraidi M, Ibriz M. [Epidemiological and clinical profile of cervical cancer in Morocco: cases in the Gharb region]. Pan Afr Med J 2023; 45:114. [PMID: 37745918 PMCID: PMC10516762 DOI: 10.11604/pamj.2023.45.114.38344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2022] [Accepted: 05/22/2023] [Indexed: 09/26/2023] Open
Affiliation(s)
- Mohamed Zraidi
- Plant, Animal and Agro-Industrial Production Laboratory, Department of Biology, Faculty of Sciences of Kenitra, Ibn Tofail University, Kenitra, Morocco University Campus, Kenitra, BP 133, Morocco
- Reference Centre for Screening and Early Diagnosis of Breast and Cervical Cancer, Kénitra Provincial Hospital, Kenitra, Morocco
| | - Mohammed Ibriz
- Plant, Animal and Agro-Industrial Production Laboratory, Department of Biology, Faculty of Sciences of Kenitra, Ibn Tofail University, Kenitra, Morocco University Campus, Kenitra, BP 133, Morocco
| |
Collapse
|
2
|
Niyonsenga G, Gishoma D, Sego R, Uwayezu MG, Nikuze B, Fitch M, Igiraneza PC. Connaissances, utilisation et obstacles liés au dépistage du cancer du col utérin dans des hôpitaux de district de Kigali, au Rwanda. Can Oncol Nurs J 2021; 31:275-284. [PMID: 34395830 DOI: 10.5737/23688076313275284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Contexte Dans le monde, le cancer du col utérin arrive au troisième rang des cancers les plus fréquents chez les femmes, mais il passe au deuxième rang en Afrique orientale, où se trouve le Rwanda. Le dépistage périodique est un moyen de prévention efficace. Malgré cela, en Afrique, on estime que le taux de dépistage de ce cancer se situe entre 10 et 70 %. Plusieurs facteurs entravent le dépistage, surtout en Afrique subsaharienne. Au Rwanda, on recense peu d'écrits sur l'utilisation des services de dépistage et les facteurs nuisant au dépistage du cancer du col utérin. Objectif Évaluer les connaissances sur le dépistage du cancer du col utérin qu'ont les femmes fréquentant les hôpitaux de district de Kigali (au Rwanda), recenser l'utilisation de ce service et déterminer les obstacles qui empêchent d'y recourir. Méthodologie Une étude transversale descriptive a été menée, et les données ont été collectées au moyen d'un questionnaire structuré. Des questions nominales de type « oui ou non » ont mis en lumière les connaissances des femmes sur le cancer du col utérin et l'utilisation des services de dépistage. Pour cerner les obstacles au dépistage, nous avons utilisé des questions de type « échelle de Likert ». Ces données ont ensuite fait l'objet d'une analyse statistique descriptive et déductive. La sélection des répondantes s'est faite par échantillonnage aléatoire systématique depuis la base de données des patientes fréquentant les services gynécologiques de trois hôpitaux de district de Kigali (Rwanda). Résultats Au total, 329 femmes ont répondu au sondage. La moitié d'entre elles (n = 165) connaissaient bien le dépistage du cancer du col utérin. Le pourcentage de dépistage se situe à 28,3 %. Nous avons décelé un lien entre l'utilisation du dépistage et une bonne connaissance du sujet (P = 0,000, r = -0,392) ainsi que certains facteurs démographiques (P = 0,000). Parmi les obstacles qui concourent à restreindre l'accès au dépistage, nous avons relevé des obstacles individuels (méconnaissance de l'existence des services de dépistage), géographiques (milieu rural) et liés au système de santé et aux prestataires de soins (campagnes de sensibilisation déficientes, attitudes négatives des prestataires de soins envers les patientes et longs délais d'attente). Conclusion Dans les hôpitaux de district étudiés de Kigali (Rwanda), on constate un faible pourcentage de dépistage du cancer du col utérin causé par plusieurs obstacles. Il est donc fortement recommandé d'engager une campagne d'information permanente sur ce cancer et son dépistage. Enfin, il est crucial que les prestataires de soins qualifiés encouragent les femmes à se soumettre au dépistage, et qu'ils s'efforcent de réduire les obstacles qui s'y rattachent.
Collapse
Affiliation(s)
| | - Darius Gishoma
- École de sciences infirmières et pratique sagefemme, Université du Rwanda, Collège de médecine et de sciences de la santé, Kigali, Rwanda
| | - Ruth Sego
- Collège des sciences infirmières Rory Meyers, Université de New York, New York, États-Unis et Faculté des sciences infirmières Bloomberg, Université de Toronto, Canada
| | - Marie Goretti Uwayezu
- École de sciences infirmières et pratique sage-femme, Université du Rwanda, Collège de médecine et de sciences de la santé, Kigali, Rwanda
| | - Bellancille Nikuze
- École de sciences infirmières et pratique sagefemme, Université du Rwanda, Collège de médecine et de sciences de la santé, Kigali, Rwanda
| | - Margaret Fitch
- École de sciences infirmières et pratique sagefemme, Université du Rwanda, Collège de médecine et de sciences de la santé, Kigali, Rwanda
| | | |
Collapse
|
3
|
Sampson CN, Nkpeebo SD, Degley TA. Connaissances, attitudes et croyances concernant le dépistage du cancer du col utérin dans le District d'Ajumako-Enyan-Essiam au Ghana. Can Oncol Nurs J 2021; 31:291-297. [PMID: 34395832 DOI: 10.5737/23688076313291297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
L'étude a été menée dans le district d'Ajumako-Eyan-Essiam (AEED) et visait à évaluer les connaissances, attitudes et croyances des femmes relativement au dépistage du cancer du col utérin. Au Ghana, ce cancer vient au deuxième rang des causes de cancer gynécologique. Dans les études et la pratique clinique effectuées auprès de femmes atteintes de cancer du col utérin, le diagnostic précoce, le traitement et la prévention du cancer sont largement influencés par leurs connaissances et leurs attitudes envers le dépistage. À ce jour, on ne dispose pas d'étude sur ces perceptions chez les femmes dans le district d'AEED. Un devis transversal quantitatif a été utilisé avec une analyse statistique descriptive de données provenant de 240 femmes. Les résultats ont révélé que 61,3 % d'entre elles ne savaient pas quel organe était touché lors d'un cancer du col utérin ou à quel intervalle un suivi était nécessaire après un résultat de test Pap normal; il y aurait donc des lacunes dans les connaissances. Au total, 36 % croyaient que le test de Papanicolaou (test Pap) était effectué une fois pour toutes, et 57,1 % pensaient qu'il était dispendieux, ce qui limite la participation au dépistage. Par peur de l'inconnu, beaucoup de répondantes avaient refusé le dépistage (48,8 %) alors que d'autres croyaient qu'elles n'étaient pas à risque (65,8 %). De plus, bon nombre de femmes (46,7 %) pensaient qu'il n'y avait pas de traitement contre le cancer du col. En conclusion, les connaissances fausses et inadéquates de ces femmes ont influencé leurs attitudes envers le dépistage du cancer.
Collapse
|
4
|
Wu L, Gong Y, Yan T, Zhang H. LINP1 promotes the progression of cervical cancer by scaffolding EZH2, LSD1, and DNMT1 to inhibit the expression of KLF2 and PRSS8. Biochem Cell Biol 2020; 98:591-599. [PMID: 32348690 DOI: 10.1139/bcb-2019-0446] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
There is a growing body of evidence indicating that long non-coding RNAs (lncRNAs) are associated with a variety of cancers. LncRNA LINP1 has been shown to be a key factor in tumor malignancy. However, the role of LINP1 in cervical cancer (CC) it is unclear. In our research, we found that the levels of LINP1 were significantly elevated in CC tissues by comparison with adjacent normal tissue. Further, the expression level of LINP1 was upregulated in CC cells compared with healthy human cervical epithelial cell lines (HUCEC). Surprisingly, we found that downregulation of LINP1 significantly reduced the proliferation of CC cells and promoted apoptosis. Additionally, downregulation of LINP1 significantly decreased CC tumor growth in vivo. Further, we observed that LINP1 recruits EZH2, LSD1, and DNMT1, thereby reducing the expression of KLF2 and PRSS8. The results from our qRT-PCR analyses showed that silencing LINP1 uprgulated the expression of KLF2 and PRSS8 in CC cells. The results from our loss-of-function assays showed that upregulation of KLF2 and PRSS8 inhibits cell proliferation and boosts cell apoptosis in CC. We also found that inhibition of KLF2 and PRSS8 reversed the inhibitory effect on cell proliferation associated with silencing LINP1. In short, LINP1 facilitates the progression of CC by suppressing KLF2 and PRSS8, and thus could provide a promising target for CC therapy.
Collapse
Affiliation(s)
- Liuli Wu
- Medical College of Guizhou University, Guiyang 550025, Guizhou, P.R. China
| | - Yuan Gong
- Department of Gynaecology, Guizhou Provincial People's Hospital, Guiyang 550002, Guizhou, P.R. China
| | - Ting Yan
- Department of Gynaecology, Guizhou Provincial People's Hospital, Guiyang 550002, Guizhou, P.R. China
| | - Huimin Zhang
- Medical College of Guizhou University, Guiyang 550025, Guizhou, P.R. China.,Department of Gynaecology, Guizhou Provincial People's Hospital, Guiyang 550002, Guizhou, P.R. China
| |
Collapse
|
5
|
Duong LM, Pham LV, Pham TT, Tran DN, Bui NQ, Tran HD, Vo TH. DNA-HPV transition rate and related factors in HPV-infected women in Can Tho city, Vietnam. Trop Med Int Health 2019; 24:1330-1334. [PMID: 31520562 DOI: 10.1111/tmi.13309] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVES To determine DNA-HPV transition rates and related factors in HPV-infected women 18-69 years of age in Can Tho City from 2013 to 2018. METHODS Both a retrospective and a prospective cohort study were done. Interviews, gynaecological examinations and HPV testing by PCR (cervical fluid) were used to collect data. The results were recorded and compared with those of HPV in 2013 to assess the development of HPV over time. Transition was defined as conversion to HPV-positive state in 2018 from a negative state in 2013. No transition was defined as clearance of HPV when the positive 2013 result was negative in 2018 or when the result remained negative or positive in 2013 and 2018. Factors related to the change were analysed. RESULTS Among a sample size of 204 cases, the average age of participants was 48.9 ± 10.4 years. Women >45 comprised 63.2% of participants; 82.8% lived with their husbands, 6.4% were divorced, and 2.9% lived apart from their husbands due to work. After 5 years of observation, 16.2% of DNA-HPV cases had converted to HPV-positive state and 66.2% of DNA-HPV cases had cleared to HPV-negative state. Factors related to conversion to HPV-positive state were age ≤ 45 years (3.14 times higher risk of transition than in the >45 age group (95% CI: 1.12-8.8)); change of sexual partner (OR = 3.75 (95% CI: 1.15-12.2)); change of sexual partner by husband (OR = 3.69 (95% CI: 1.20-11.3); sexually transmitted diseases (OR = 5.19 (95% CI: 1.09-24.8)); and a history of vacuum aspiration or dilation and evacuation abortion (OR = 1.4 (95% CI: 0.29-6.4)). CONCLUSIONS 16.2% of women with DNA-HPV transition converted to HPV-positive state. Changes in sexual habits increase the risk of developing HPV positivity.
Collapse
Affiliation(s)
- Linh My Duong
- Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam
| | - Linh Van Pham
- Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam
| | - Tam Thi Pham
- Department of Public Health, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam
| | - Dung Ngoc Tran
- Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam
| | - Nghia Quang Bui
- Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam
| | - Hung Do Tran
- Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam
| | - Trang Huynh Vo
- Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam
| |
Collapse
|
6
|
Diabaté K, Camara F, Sidibé FM, Diarra IM, Koné AS, Diakité A, Bathily M, Ly M, Sima M, Traoré A, Sidibé S, Diallo DA. [Neoadjuvant chemotherapy in locally advanced cervical cancer in patients receiving a concomitant chemoradiotherapy in a low income country]. Mali Med 2019; 34:39-43. [PMID: 35897220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
PURPOSE Delays to access to radiotherapy are long in our context. The purpose of this study was to analyze the effect of neoadjuvant chemotherapy to concomitant chemoradiotherapy in locally advanced cervical cancers. PATIENTS AND METHODS We conducted a retrospective study from April 2014 to April 2016 at the radiotherapy center of "Hopital du Mali" in Bamako, Mali. Patients were allocated according to age, histological type, tumor size and the 2002 classification of the FIGO. Experimental protocol was the administration of a neoadjuvante chemotherapy with association of Paclitaxel 175mg/m2 + Carboplatine AUC 5 every 3 weeks and radiothérapy cure with avec linac 6 MV at 70 Gy due to 5 sessions of 2 Gy per week associated with a concomitant chemotherapy with cisplatin at 40 mg/m2/week. The clinical response was assessed at the end of neoadjuvant chemotherapy and of concomitant chemoradiotherapy. RESULTS Thirty patients were included in the study. The mean age was 53.63 ± 8.9 years. The mean size of the tumor was 5.17 cm (2 to 7 cm). According to the 2002 classification of the FIGO stages IIB were 33% (n = 10); IIIB were 57% (n = 17) and IVA were 10% (n = 3). Clinical evaluation at the end of neoadjuvant chemotherapy found: complete response 17 % (n = 5), partial response 10% (n = 3) and stable disease 73 % (n = 22). Evaluation at the end of the concomitant chemoradiotherapy had found the complete response in 90% (n = 27) and stable disease in 10% (n = 3). CONCLUSION Neoadjuvant chemotherapy to concomitant chemoradiotherapy in locally advanced cervical cancer allows stabilization of the tumor and improves local control. Due to long delays to access to radiotherapy treatment in our context; neoadjuvant chemotherapy is an alternative to stabilize the disease and prevent distant metastasis from locally advanced cervical cancers.
Collapse
Affiliation(s)
- K Diabaté
- Service radiothérapie Hôpital du Mali
| | - F Camara
- Nutrition clinique et science des aliments Bamako-Mali
| | - F M Sidibé
- Service hémato-oncologie CHU Point G Bamako-Mali
| | | | - A S Koné
- Service radiothérapie Hôpital du Mali
| | - A Diakité
- Service radiothérapie Hôpital du Mali
| | - M Bathily
- Service hémato-oncologie CHU Point G Bamako-Mali
| | - M Ly
- Service d'oncologie médicale CHU Luxembourg Bamako-Mali
| | - M Sima
- Service gynécologie et obstétrique CHU Point G Bamako-Mali
| | - A Traoré
- Service de gynécologie et obstétrique Hôpital du Mali
| | - S Sidibé
- Service de radiologie CHU Point G Bamako-Mali
| | - D A Diallo
- Service hémato-oncologie CHU Point G Bamako-Mali
| |
Collapse
|
7
|
Vijayaraghavan A, Efrusy MB, Mayrand MH, Santas CC, Goggin P. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Québec, Canada. Can J Public Health 2010; 101:220-5. [PMID: 20737813 PMCID: PMC6973910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 08/31/2009] [Accepted: 02/05/2010] [Indexed: 11/14/2023]
Abstract
OBJECTIVES Human papillomavirus (HPV) testing is not widely used for triage of equivocal Pap smears or primary screening in Québec, Canada. Our objective was to evaluate the cost-effectiveness of cervical cancer screening strategies utilizing HPV testing. METHODS We used a lifetime Markov model to estimate costs, quality of life, and survival associated with the following strategies: 1) cytology; 2) cytology with HPV testing to triage equivocal Pap smears; 3) HPV testing followed by colposcopy for HPV-positive women; 4) HPV testing with cytology to triage HPV-positive women; and 5) simultaneous HPV testing and cytology. Cytology was used in all strategies prior to age 30. Outcome measures included disease incidence, quality-adjusted life-years saved (QALYs), lifetime risk of cervical cancer, and incremental cost-effectiveness ratios. RESULTS All strategies incorporating HPV testing as a primary screening test were more effective and less expensive than annual cytology alone, while HPV testing to triage equivocal Pap smears annually was very cost-effective ($2,991 per QALY gained compared to annual cytology alone). When compared to cytology every three years, HPV-based strategies cost an additional $8,200 to $13,400 per QALY gained. CONCLUSION Strategies incorporating HPV testing are not only more effective than screening based on cytology alone but are also highly cost-effective. Provincial policy-makers should evaluate incorporating HPV-based strategies into current cervical cancer screening guidelines.
Collapse
|